TEBICA003 TNBCESTUDIO CLÍNICO FASE I DE INMUNOTERAPIA CON VACUNAS SINTÉTICAS PERSONALIZADAS EN PACIENTES CON CÁNCER DE MAMA TRIPLE NEGATIVO

This study focuses on creating personalized synthetic vaccines as a treatment option for patients with triple-negative breast cancer (TNBC). TNBC is a challenging type of breast cancer that lacks certain receptors, making it difficult to treat with standard chemotherapy or radiation. This type of cancer is aggressive and has a high rate of mutations, which makes it more likely to resist typical treatments. The goal of this study is to explore how personalized vaccines, designed using the specific mutations found in a patient’s tumor, could potentially improve treatment outcomes. By harnessing the body's immune system to recognize and attack cancer cells, researchers hope to develop a more targeted therapy that could offer better survival rates and quality of life for patients. Participants in this study will undergo a process where the unique mutations in their tumors are identified through an analysis of the tumor's genetic material. Based on this information, a personalized vaccine is created, incorporating peptides that act as neo-antigens—newly created antigens that the immune system can target. This vaccine is then administered to the patient, aiming to stimulate their immune system to recognize and destroy the cancer cells. The study is in its early phase, primarily focusing on assessing the safety and immune response triggered by these vaccines. By determining how well these vaccines work in activating the immune system without causing harm, the study could pave the way for more personalized cancer treatments.